Antiva Biosciences
Stopping Cancer Before It Starts
South San Francisco, United States · Founded 2012 · $121.0M raised
- Headquarters
- South San Francisco, California
- Employees
- 11–50
- Founded
- 2012
- Business Model
- B2B
- Website
- antivabio.com
- Total Funding
- $121.0M
- Last Round
- $53.0M Series EApr 2023
- Rounds
- 4
About
Antiva Biosciences is a clinical-stage biopharmaceutical company developing novel topical therapeutics for the treatment of oncogenic HPV infections and pre-cancerous cervical lesions. Their lead therapy aims to give women a non-surgical, at-home treatment option — the first approved drug treatment for HPV infection — supporting the WHO's global Cervical Cancer Elimination Initiative.
Summary
Antiva Biosciences is a Biotech company based in South San Francisco, United States, founded in 2012. It has raised $121.0M in total across 4 rounds, most recently a $53.0M Series E round in Apr 2023. Investors include MPM BioImpact, HBM Partners and Sirona Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Apr 2023
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...